瑞普生物(300119.SZ):重組新城疫病毒滅活疫苗(A-VII株)取得獸藥產品批准文號
格隆匯 10 月 22日丨瑞普生物(300119.SZ)公佈,公司空港經濟區分公司近日獲得了由農業農村部核發的獸藥產品批准文號,商品名稱為優金安;獸藥通用名稱為重組新城疫病毒滅活疫苗(A-VII株)。
重組新城疫病毒滅活疫苗(A-VII株)中含滅活的新城疫病毒A-VII株,用於預防雞、鵝的新城疫。該產品是應用反向遺傳技術成功研製的國家一類新獸藥“重組新城疫病毒滅活疫苗(A-VII株)”。A-VII株與流行毒株基因型完全匹配,免疫原性好,不僅能保護免疫動物不發病、不死亡,而且能大幅降低攻毒後動物的病毒載量和排毒率,從而有效防止疫病傳播,同時,A-VII株誘導機體產生特異性HI抗體的速度和水平顯著高於其它毒株;對雞和鵝的新城疫都有很好的保護效果。
該獸藥產品批准文號的獲得,進一步完善了公司產品結構,實現了公司新城疫疫苗毒株的更新,提升了公司產品的整體競爭力與行業地位,將促進公司家禽產品市場佔有率的持續提升,也將對公司未來經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.